Rappel de Free T4 Controls (9C03-10);T4 Free Reagent IMx (2222-20)

Selon L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), ce/cet/cette rappel concerne un dispositif en/au/aux/à France qui a été fabriqué par ABBOTT DIAGNOSTIC.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • Date
    2003-06-06
  • Pays de l'événement
  • Source de l'événement
    ANSM
  • URL de la source de l'événement
  • Notes / Alertes
    French data is current through early September 2018. All of the data comes from L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and France.
  • Notes supplémentaires dans les données
  • Action
    ABBOTT DIAGNOSTIC withdraws from the market batches 95881Q100 and 95881Q101 (expiry date 11 February 2004) of the in vitro diagnostic medical device called Free T4 Controls (9C03-10) and lot 01550Q100 (October 28, 2003 expiry) of the device called T4 Free Reagent IMx (2222-20) due to values ​​outside the expected limits on AxSYM or IMx. Only on IMx, the simultaneous use of these batches of controls and reagent can result in a decrease in patient results up to 30% of their value with controls within the expected limits. These devices are used in the microparticulate immunoenzymological assay (MEIA) for the quantitative measurement of free thyroxine in serum or human heparinized plasma.

Device

  • Modèle / numéro de série
  • Description du dispositif
    in-vitro_medical_device
  • Manufacturer

Manufacturer

  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    LAANSM